Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina    ILMN

ILLUMINA (ILMN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies

Anaïs Lozach

Analyst
 
share with twitter share with LinkedIn share with facebook
share via e-mail

The trend should regain control

Strategy published on 02/16/2018 | 14:10
long trade
Live
Entry price : 228.85$ | Target : 270$ | Stop-loss : 208.7$ | Potential : 17.98%
The timing appears opportune to go long in shares of Illumina as we anticipate another pick-up in the underlying trend.
Investors have an opportunity to buy the stock and target the $ 270.
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Historically, the company has been releasing figures that are above expectations.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 217.19 USD
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 253.91.
  • Technically, the stock approaches a strong medium-term resistance at USD 253.91.
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 57.91 times its estimated earnings per share for the ongoing year.
Ratings chart
Sector Advanced Medical Equipment & Technology - NEC
1st jan.Capitalisation (M$)Investor Rating
ILLUMINA12.52%35 894
THERMO FISHER SCIENTIFIC13.70%86 857
DANAHER CORPORATION9.18%70 780
INTUITIVE SURGICAL22.72%51 587
BOSTON SCIENTIFIC CORPORATI..16.34%39 785
ROYAL PHILIPS10.18%37 856
EDWARDS LIFESCIENCES CORPOR..21.72%28 860
AGILENT TECHNOLOGIES0.87%21 783
CERNER CORPORATION-13.10%19 317
WATERS CORPORATION7.77%16 302
RESMED16.66%14 121
ABIOMED, INC.63.24%13 545
OLYMPUS CORP-9.68%12 599
VARIAN MEDICAL SYSTEMS14.34%11 569
HOLOGIC-10.11%10 587
PERKINELMER2.67%8 244
More Results
Financials ($)
Sales 2018 3 136 M
EBIT 2018 824 M
Net income 2018 626 M
Finance 2018 1 348 M
Yield 2018 -
P/E ratio 2018 57,91
P/E ratio 2019 49,83
EV / Sales 2018 11,0x
EV / Sales 2019 9,74x
Capitalization 35 894 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ILLUMINA
Duration : Period : Day
Illumina Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
Duration : Period : Week
Illumina Technical Analysis Chart | ILMN | US4523271090 | 4-Traders